Une étude visant à tester différentes doses de BI 1810631 chez des personnes atteintes de différents types de cancer avancé (tumeurs solides avec modifications du gène HER2)
Un essai ouvert de phase I d'escalade de dose, avec confirmation et extension de dose, du BI 1810631 en monothérapie chez des patients atteints de tumeurs solides avancées ou métastatiques avec des aberrations HER2
The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful.
The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene.
The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink.
In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day.
The participants are in the study for as long as they benefit from and can tolerate treatment.
Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Additional US locations available on demand. Please contact for options.
- Numéro de téléphone: 1-800-243-0127
Sauvegarde des contacts de l'étude
- Nom: Boehringer Ingelheim
- Numéro de téléphone: 1-800-243-0127
- E-mail: clintriage.rdg@boehringer-ingelheim.com
Lieux d'étude
-
-
-
Augsburg, Allemagne, 86156
- Complété
- Universitätsklinikum Augsburg
-
Cologne, Allemagne, 50937
- Recrutement
- Universitätsklinikum Köln (AöR)
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
Dresden, Allemagne, 01307
- Recrutement
- Technische Universität Dresden
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
Giessen, Allemagne, 35392
- Recrutement
- Justus-Liebig Universität Gießen
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
Oldenburg, Allemagne, 26121
- Recrutement
- Pius-Hospital, Oldenburg
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 08007234742
- E-mail: deutschland@bitrialsupport.com
-
-
-
-
New South Wales
-
Macquarie Park, New South Wales, Australie, 2109
- Complété
- Macquarie University
-
-
-
-
-
Anderlecht/Brussels-Capital, Belgique, 1070
- Actif, ne recrute pas
- Brussels - HOSP Jules Bordet
-
-
-
-
-
Beijing, Chine, 100036
- Complété
- Beijing Cancer Hospital
-
Changchun, Chine, 130021
- Actif, ne recrute pas
- The First Hospital of Jilin University
-
Changchun, Chine, 130012
- Complété
- Jilin Province Cancer Hospital
-
Fuzhou, Chine, 350014
- Actif, ne recrute pas
- Fujian Cancer Hospital
-
Guangzhou, Chine, 510080
- Actif, ne recrute pas
- Guangdong Provincial People's Hospital
-
Hangzhou, Chine, 310022
- Actif, ne recrute pas
- Zhejiang Cancer Hospital
-
Hangzhou, Chine, 310003
- Actif, ne recrute pas
- The First Affiliated Hospital, Zhejiang University
-
Harbin, Chine, 150081
- Actif, ne recrute pas
- Harbin Medical University Cancer Hospital
-
Nanning, Chine, 530021
- Complété
- The Affiliated Cancer Hospital, Guangxi Medical University
-
Shanghai, Chine, 200030
- Complété
- Shanghai Chest Hospital
-
Wuhan, Chine, 430030
- Actif, ne recrute pas
- Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
-
Wuhan, Chine, 430022
- Actif, ne recrute pas
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Xiamen, Chine, 361003
- Complété
- First Affiliated Hospital of Xiamen University
-
Zhengzhou, Chine, 450052
- Actif, ne recrute pas
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Chine, 450008
- Actif, ne recrute pas
- Henan Cancer Hospital
-
-
-
-
-
Chungju, Corée du Sud, 28644
- Recrutement
- Chungbuk National University Hospital
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 0808802084
- E-mail: namhan@bitrialsupport.com
-
Seongnam, Corée du Sud, 13620
- Recrutement
- Seoul National University Bundang Hospital
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 0808802084
- E-mail: namhan@bitrialsupport.com
-
Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 0808802084
- E-mail: namhan@bitrialsupport.com
-
Seoul, Corée du Sud, 06351
- Recrutement
- Samsung Medical Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 0808802084
- E-mail: namhan@bitrialsupport.com
-
Seoul, Corée du Sud, 03722
- Actif, ne recrute pas
- Severance Hospital
-
-
-
-
-
Barcelona, Espagne, 08035
- Actif, ne recrute pas
- Hospital Universitari Vall d'Hebron
-
L'Hospitalet de Llobregat, Espagne, 08907
- Actif, ne recrute pas
- Hospital Duran i Reynals
-
Madrid, Espagne, 28041
- Actif, ne recrute pas
- Hospital Universitario 12 de Octubre
-
Madrid, Espagne, 28007
- Complété
- Hospital General Universitario Gregorio Marañón
-
Málaga, Espagne, 29010
- Actif, ne recrute pas
- Hospital Universitario Virgen de la Victoria
-
Valencia, Espagne, 46010
- Actif, ne recrute pas
- Hospital Clinico Universitario de Valencia
-
-
-
-
-
Bron, France, 69677
- Actif, ne recrute pas
- Hopital Louis Pradel
-
Lyon, France, 69373
- Actif, ne recrute pas
- CTR Leon Berard
-
Marseille, France, 13385
- Actif, ne recrute pas
- HOP Timone
-
Paris, France, 75005
- Actif, ne recrute pas
- INS Curie
-
Rennes, France, 35000
- Actif, ne recrute pas
- HOP Pontchaillou
-
Villejuif, France, 94805
- Actif, ne recrute pas
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hong Kong
- Actif, ne recrute pas
- Queen Mary Hospital
-
Hong Kong, Hong Kong, 999077
- Actif, ne recrute pas
- Prince of Wales Hospital-Hong Kong-20715
-
-
-
-
-
Haifa, Israël, 3109601
- Complété
- Rambam Medical Center
-
Kfar Saba, Israël, 44281
- Complété
- Meir Medical Center
-
Tel Aviv, Israël, 6423906
- Actif, ne recrute pas
- Sourasky Medical Center
-
Tel HaShomer, Israël, 52621
- Complété
- The Chaim Sheba Medical Center Tel HaShomer
-
-
-
-
-
Candiolo (TO), Italie, 10060
- Complété
- Istituto Di Candiolo
-
Naples, Italie, 80131
- Complété
- Istituto Nazionale IRCCS Tumori Fondazione Pascale
-
Parma, Italie, 43100
- Complété
- Azienda Ospedaliera Unversitaria di Parma
-
-
-
-
-
Chiba, Kashiwa, Japon, 277-8577
- Recrutement
- National Cancer Center Hospital East
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Ehime, Matsuyama, Japon, 791-0280
- Recrutement
- Shikoku Cancer Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Hiroshima, Hiroshima, Japon, 734-8551
- Recrutement
- Hiroshima University Hospital
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Osaka, Osaka, Japon, 541-8567
- Recrutement
- Osaka International Cancer Institute
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Osaka, Sakai, Japon, 590-0197
- Recrutement
- Kindai University Hospital
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Shizuoka, Hamamatsu, Japon, 431-3192
- Recrutement
- Hamamatsu University Hospital
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
Tokyo, Chuo-ku, Japon, 104-0045
- Recrutement
- National Cancer Center Hospital
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 05050508862
- E-mail: nippon@bitrialsupport.com
-
-
-
-
-
Linz, L'Autriche, 4020
- Complété
- Ordensklinikum Linz GmbH
-
-
-
-
-
Porto, Le Portugal, 4100-180
- Complété
- Hospital CUF Porto
-
-
-
-
-
Amsterdam, Pays-Bas, 1066 CX
- Recrutement
- Nederlands Kanker Instituut
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 08000204613
- E-mail: nederland@bitrialsupport.com
-
Leiden, Pays-Bas, 2333 ZA
- Actif, ne recrute pas
- Leids Universitair Medisch Centrum (LUMC)
-
-
-
-
-
London, Royaume-Uni, SW3 6JJ
- Actif, ne recrute pas
- The Royal Marsden Hospital, Chelsea
-
London, Royaume-Uni, W12 0HS
- Actif, ne recrute pas
- Hammersmith Hospital
-
Sutton, Royaume-Uni, SM2 5PT
- Actif, ne recrute pas
- The Royal Marsden Hospital, Sutton
-
-
-
-
-
Singapore, Singapour, 169610
- Recrutement
- National Cancer Centre Singapore
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 8001207344
- E-mail: singapore@bitrialsupport.com
-
Singapore, Singapour, 119228
- Complété
- National University Hospital-Singapore-22806
-
-
-
-
-
Stockholm, Suède, 171 76
- Complété
- Karolinska Universitetssjukhuset Solna
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Recrutement
- University of Alabama at Birmingham
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
California
-
Beverly Hills, California, États-Unis, 90212
- Complété
- Precision NextGen Oncology
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope-Duarte-56419
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
Huntington Beach, California, États-Unis, 92648
- Complété
- City of Hope - Seacliff
-
Irvine, California, États-Unis, 92618
- Complété
- City of Hope-Irvine-69674
-
Los Angeles, California, États-Unis, 90067
- Recrutement
- Valkyrie Clinical Trials
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
Orange, California, États-Unis, 92868
- Recrutement
- University of California Irvine
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
Sacramento, California, États-Unis, 95817
- Recrutement
- University of California Davis
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- Recrutement
- Georgetown University
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33308
- Recrutement
- Holy Cross Hospital-Fort Lauderdale-57892
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Winship Cancer Institute
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- Recrutement
- Hawaii Cancer Care - Honolulu
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
New York
-
New York, New York, États-Unis, 10016
- Recrutement
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Recrutement
- Duke University Medical Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Recrutement
- Cleveland Clinic
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Sarah Cannon Research Institute-Nashville-48456
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Texas
-
Dallas, Texas, États-Unis, 75230
- Recrutement
- Mary Crowley Cancer Research Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
Houston, Texas, États-Unis, 77030
- Recrutement
- The University of Texas MD Anderson Cancer Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Virginia Cancer Specialists, PC
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- Fred Hutchinson Cancer Research Center
-
Contact:
- Boehringer Ingelheim
- Numéro de téléphone: 833-602-2368
- E-mail: unitedstates@bitrialsupport.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic non-haematologic malignancy. Patient must show presence of at least one measurable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
-
Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 (ECOG=2 only for Cohorts 6, 7 and 9) .
-
Availability and patient willingness to provide a sample of tumour for confirmation of the patient´s Human epidermal growth factor receptor 2 (HER2) status. This sample can be archival material obtained at any time prior to study enrollment.
-
Patient willing and able to comply with the protocol requirements for tumour biopsies (biopsies from brain metastases are not allowed).
-
Adequate organ function defined as all of the following:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (≥ 1.5 x 10^3/μL) (≥ 1500/mm^3); haemoglobin ≥ 9.0 g/dL (≥ 90 g/L) (≥ 5.6 mmol/L); platelets ≥ 100 x 10^9/L (100 x 10^3/μL) (100 x 10^3/mm3) without the use of hematopoietic growth factors within 4 weeks of start of trial medication.
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except for patients with Gilbert's syndrome: total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN.
- Estimated Glomerular Filtration Rate (eGFR) ≥ 50 mL/min - calculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula (≥ 30 mL/min/1.73m² for cohorts 6, 8, and 9).
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.
- Alkaline Phosphatase < 5 x ULN.
-
Recovered from any previous therapy-related toxicity to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at start of treatment (except for alopecia, stable sensory neuropathy and hypothyroidism (patients on thyroid replacement therapy) which must be ≤ CTCAE Grade 2)
-
Life expectancy of at least 12 weeks at the start of treatment in the opinion of the investigator.
-
At least 18 years of age at the time of consent or over the legal age of consent in countries where that is greater than 18 years.
-
Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
-
Male or female patients. Women of childbearing potential (WOCBP) and men who are able to father a child must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
Additional inclusion criteria for Phase Ia
- Patients with a documented diagnosis of HER2 aberration: overexpression OR gene amplification OR non-synonymous somatic mutation OR gene rearrangement involving HER2 or Neuregulin 1 (NRG1)
- Patient who has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted, or not be a suitable candidate for, available treatment options known to prolong survival for their disease
Additional inclusion criteria for Phase Ib - Cohort 1 only
- Non-squamous non-small cell lung cancer (NSCLC) patients with documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain (TKD) as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with non-squamous NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Additional inclusion criteria for Phase Ib - Cohort 2 only
- Non-squamous NSCLC patient with a documented HER2 mutation in the tyrosine kinase domain (TKD) as per local lab results.
- Treatment naïve for non-squamous NSCLC.
Additional inclusion criteria for Phase Ib - Cohort 3 only
- NSCLC Patient with a documented HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results or squamous NSCLC patient with mutation in the TKD as per local lab results. After implementation of CTP v8, only non-squamous NSCLC patients with a documented activating HER2 mutation outside of the tyrosine kinase domain (TKD) as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy. After implementation of CTP v8, patients who had received, in the advanced/metastatic setting, at least one line of systemic therapy OR patients who are treatment naïve for non-squamous NSCLC (no prior systemic therapy, immunotherapy or targeted therapy for stage IIIB or IV adenocarcinoma).
Additional inclusion criteria for Phase Ib - Cohort 4 only
- NSCLC patients with documented HER2 mutation in the TKD as per local lab results.
- NSCLC patients who are either treatment naïve or who had received any prior line of treatment, in the advanced/metastatic setting. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
- Patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
Additional inclusion criteria for Phase Ib - Cohort 5 only
- Non-squamous NSCLC patients with documented HER2 mutation in the TKD as per local lab results.
- Patient should have received, in the advanced/metastatic setting, at least one line of systemic therapy that includes a platinum-based combination chemotherapy and should have been treated with previous HER2 directed antibody-drug conjugates (ADC) in the same advanced/metastatic setting and developed disease progression recurrence during or after completing this therapy. Patients with NSCLC harboring additional genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Additional inclusion criteria for Phase Ib - Cohort 6 only
- Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy.
- Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
- Patient who is not eligible for any other recruiting cohort.
Additional inclusion criteria for Phase Ib - Cohort 7 only
- Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy.
- Patient without active brain metastases or patient with active brain metastases who are not eligible for immediate local therapy, as per investigator evaluation.
- Patient who is not eligible for any other recruiting cohort.
Additional inclusion criteria for Phase Ib - Cohort 8 only
- Treatment naïve for NSCLC
- NSCLC (adenocarcinoma or squamous) patient with documented HER2 mutation in the tyrosine kinase domain (TKD) or non-squamous NSCLC with a documented HER2 mutation in the non tyrosine kinase domain (non TKD) as per local lab results
Additional inclusion criteria for Phase Ib - Cohort 9 only
- Non-squamous NSCLC patient with documented HER2 mutation in the TKD as per local lab results.
- Patient who had received, in the advanced/metastatic setting, at least one line of systemic therapy. Patients with NSCLC harboring additionally genomic aberrations for which approved targeted therapy is available as standard of care, must have received prior treatment with an approved targeted therapy.
Further inclusion criteria apply.
Exclusion Criteria:
-
Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to first trial treatment or planned within 6 months after screening
-
Previous or concomitant malignancies other than the one treated in this trial within the last 2 years, except:
- effectively treated non-melanoma skin cancers
- effectively treated carcinoma in situ of the cervix
- effectively treated ductal carcinoma in situ
- other effectively treated malignancy that is considered cured by local treatment.
-
Treatment with a systemic anti-cancer therapy or investigational drug within 21 days or 5 half-lives (whichever is shorter) of the first treatment with the study medication
-
Patients who must or wish to continue the intake of restricted medication or any drug considered likely to interfere with the safe conduct of the trial
-
Previous treatment with zongertinib.
-
Radiotherapy within 2 weeks prior to first study treatment, except palliative radiotherapy to regions other than the chest, which is allowed up to 1 week prior to first study treatment.
Further exclusion criteria apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Phase Ib - Partie d'extension de dose : Cohorte 1
|
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Partie d'extension de dose : Cohorte 2
|
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Partie extension de dose : Cohorte 3
|
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Partie extension de dose : Cohorte 4
|
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Partie d'extension de dose : Cohorte 5
|
zongertinib
Autres noms:
|
|
Expérimental: Phase Ia - Dose escalation part
Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy. |
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Dose expansion part: Cohort 6
Cohort only in the United States of America (USA) |
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Dose expansion part: Cohort 7
Cohort only in Japan |
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Dose expansion part: Cohort 8
Cohort only in the United States of America (USA) |
zongertinib
Autres noms:
|
|
Expérimental: Phase Ib - Dose expansion part: Cohort 9
Cohort only in China |
zongertinib
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase Ia : nombre de patients présentant des toxicités limitant la dose (DLT) au cours de la période d'évaluation MTD
Délai: A la fin du cycle 1 (chaque cycle est de 21 jours).
|
A la fin du cycle 1 (chaque cycle est de 21 jours).
|
|
|
Phase Ib : Cohorte 4 : Réponse objective selon l'évaluation de la réponse en neuro-oncologie pour les métastases cérébrales (RANO-BM) par une revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ia: Maximum Tolerated Dose (MTD)
Délai: At the end of Cycle 1 (each cycle is 21 days).
|
Maximum tolerated dose is defined as the highest dose with less than 25% risk of the true Dose Limiting Toxicity (DLT) rate being equal to or above 33% during the MTD evaluation period in any studied regimen. |
At the end of Cycle 1 (each cycle is 21 days).
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response (OR) as assessed by central independent review
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
OR is defined as best overall response of complete response (CR) or partial response (PR), where best overall response is determined according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, from the first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 3 (patients prior to CTP v8.0), 6, 7, 8, and 9: Objective response according to RECIST 1.1 by investigator assessment
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
Clincal Trial Protocol version 8.0 = CTP v8.0 |
From the start of the trial treatment until end of month 12, up to 12 months.
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase Ia : Nombre de patients subissant des DLT pendant toute la période de traitement
Délai: Du début du traitement d'essai jusqu'à la fin du mois 8, jusqu'à 8 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 8, jusqu'à 8 mois.
|
|
|
Phase Ib - Cohorte 4 : Durée de réponse objective (DoR) selon RANO-BM par revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Cohorte 4 : Contrôle de la maladie (DC) selon RANO-BM par revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Cohorte 4 : Survie sans progression (PFS) selon RANO-BM telle qu'évaluée par une revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Cohorte 4 : RO selon RECIST 1.1 par revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Cohorte 4 : Durée de la RO selon RECIST 1.1 par revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Cohorte 4 : DC selon RECIST 1.1 par revue centrale indépendante
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Toutes les cohortes : Nombre de patients subissant des DLT pendant toute la période de traitement
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Toutes les cohortes : changement du score du domaine de fonctionnement physique du questionnaire de base sur la qualité de vie de l'EORTC (EORTC QLQ-C30) entre le début et le jour 1 du cycle 5
Délai: Au départ et au jour 1 du cycle 5 (chaque cycle dure 21 jours).
|
Au départ et au jour 1 du cycle 5 (chaque cycle dure 21 jours).
|
|
|
Phase Ib - Toutes les cohortes : modification du score total du questionnaire d'évaluation des symptômes du cancer du poumon non à petites cellules (NSCLC-SAQ) entre le début et le jour 1 du cycle 5
Délai: Au départ et au jour 1 du cycle 5 (chaque cycle dure 21 jours).
|
Au départ et au jour 1 du cycle 5 (chaque cycle dure 21 jours).
|
|
|
Phase Ib – Toutes les cohortes : changement entre le début et le jour 1 du cycle 5 dans le score de la liste 46 des éléments de l'EORTC (IL46)
Délai: Au départ et au jour 1 du cycle 5 (chaque cycle dure 21 jours).
|
Au départ et au jour 1 du cycle 5 (chaque cycle dure 21 jours).
|
|
|
Phase Ia : concentration maximale mesurée de zongertinib dans le plasma (Cmax)
Délai: Le jour 1 et le jour 15 du cycle 1 (chaque cycle dure 21 jours).
|
Le jour 1 et le jour 15 du cycle 1 (chaque cycle dure 21 jours).
|
|
|
Phase Ia : aire sous la courbe concentration-temps du zongertinib dans le plasma (ASC0-t2)
Délai: Le jour 1 et le jour 15 du cycle 1 (chaque cycle dure 21 jours).
|
Le jour 1 et le jour 15 du cycle 1 (chaque cycle dure 21 jours).
|
|
|
Phase Ib - Toutes les cohortes : survie globale (SG), définie comme le temps écoulé entre la première administration du traitement et le décès, quelle qu'en soit la cause.
Délai: Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement d'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase IB - Cohorte 4: PFS selon RECIST 1.1 par Central Independent Review
Délai: Du début du traitement de l'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
Du début du traitement de l'essai jusqu'à la fin du mois 12, jusqu'à 12 mois.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Duration of objective response (DoR) according to RECIST 1.1
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
DoR is defined as the time from first documented complete response (CR) or partial response (PR) until the earliest of disease progression or death among patients with objective response as assessed by central independent review. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control (DC)
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
DC is defined as best overall response of complete response (CR) or partial response (PR) or stable disease (SD) where best overall response is defined according to RECIST version 1.1 as assessed central independent review, from first treatment administration until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Progression-free survival (PFS)
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
PFS is defined as the time from first treatment administration until tumor progression according to RECIST version 1.1 as assessed by central independent review, or death from any cause, whichever occurs earlier. |
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response according to response assessment in RANO-BM criteria as assessed by central independent review for patients with central nervous system (CNS) lesions at baseline
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control according to RANO-BM criteria as assessed by central independent review for patients with CNS lesions at baseline
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Objective response in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baseline
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 1, 2, 3 (enrolled from CTP v8.0), and 5: Disease control in CNS lesions according to RECIST 1.1 criteria as assessed by central independent review for patients with CNS lesions at baseline
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Duration of objective response according to RECIST 1.1 by investigator assessment
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RECIST 1.1 as assessed by the investigator
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Progression-free survival according to RECIST 1.1 as assessed by the investigator
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Objective response according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baseline
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohorts 3 (enrolled before CTP v8.0), 6, 7, 8 and 9: Disease control according to RANO-BM criteria as assessed by the investigator for patients with CNS lesions at baseline
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohort 4: DoR in CNS lesions according to RECIST 1.1 by central independent review
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohort 4: DC in CNS lesions according to RECIST 1.1 by central independent review
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
|
|
Phase Ib - Cohort 4: PFS in CNS lesions according to RECIST 1.1 as assessed by central independent review
Délai: From the start of the trial treatment until end of month 12, up to 12 months.
|
From the start of the trial treatment until end of month 12, up to 12 months.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Publications générales
- Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, Wu YL, Cho BC, Yamamoto N, Sabari JK, Zhao Y, Tu HY, Yoh K, Nadal E, Sadrolhefazi B, Rohrbacher M, von Wangenheim U, Eigenbrod-Giese S, Zugazagoitia J; Beamion LUNG-1 Investigators. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025 Jun 19;392(23):2321-2333. doi: 10.1056/NEJMoa2503704. Epub 2025 Apr 28.
- Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, Schroter L, Botilde Y, Sadrolhefazi B, Serra J, Yoh K, Yamamoto N. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. J Clin Oncol. 2025 Apr 10;43(11):1337-1347. doi: 10.1200/JCO-24-01727. Epub 2025 Mar 3.
- Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, Yamamoto N. A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Clin Lung Cancer. 2023 Mar;24(2):e65-e68. doi: 10.1016/j.cllc.2022.10.008. Epub 2022 Nov 11.
- Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, Nadal E, Wu YL, Zugazagoitia J, Tu HY, Baik CS, Yoh K, Soo RA, Zhao Y, Sabari JK, Wermke M, Scheffler M, Ahn MJ, Fernamberg K, Schroeter L, Sadrolhefazi B, Thamer C, Eigenbrod-Giese S, Popat S; Beamion LUNG-1 Investigators. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026 Apr 30;394(17):1675-1684. doi: 10.1056/NEJMoa2516969. Epub 2026 Apr 15.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Processus néoplasiques
- Tumeurs pulmonaires
- Carcinome bronchique
- Tumeurs bronchiques
- Conditions pathologiques, signes et symptômes
- Métastase néoplasmique
- Carcinome pulmonaire non à petites cellules
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 1479-0001
- 2020-004563-47 (Numéro EudraCT)
- 2024-511246-39-00 (Identificateur de registre: CTIS (EU))
- U1111-1312-5969 (Identificateur de registre: WHO International Clinical Trials Registry Platform (ICTRP))
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).
For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .